The global competition for ROR1-targeted therapies is underway. MSD's zilovertamab vedotin (ADC) is in the lead, while CStone Pharmaceuticals' CS5001, licensed from LegoChem Biosciences, is in the clinical stage. EpimAb Biotherapeutics' EMB-07 is the clinical-stage leader in the ROR1/CD3 bispecific T-cell engager (TCE) track.

Zhejiang Shuyou Surgical Instrument Co., Ltd. (Stock Code: 874379), a leading Chinese electrosurgical device manufacturer, has filed its IPO prospectus for listing on the Beijing Stock Exchange. The company specializes in R&D, production, and global sales of surgical dissectors and accessories, with a portfolio spanning over 1,000 specifications across four major product lines. Backed by 123 authorized patents—including core technology from a National Technology Invention Award—the firm serves top-tier hospitals in China and international clients like Medline and CONMED. Despite modest revenue growth (¥216.1M in FY2025) and margin pressure from centralized procurement policies, Shuyou maintains strong profitability (¥66.5M net profit) and a low debt ratio (8.71%). The IPO aims to raise ¥350.5M to expand production capacity, enhance R&D, and upgrade its marketing network. Founder Su Ying and her daughter Wang Su retain 92.71% voting control, reflecting a highly concentrated ownership structure.

Likang Life Sciences has broken ground on a 110 million yuan drug research and production center in the Beijing Economic-Technological Development Area. Expected to be operational by October 2026, the facility will house China's first production line for AI-powered personalized tumor vaccines. By integrating artificial intelligence with precision oncology, the project aims to accelerate antigen identification and streamline vaccine manufacturing, aligning with China's strategy to advance its biopharmaceutical sector and lead in personalized medicine.

NeuroGen Pharma Limited, a China-focused specialty pharma company specializing in neurology, pain, and allergy therapeutics, has filed for an IPO on the Hong Kong Stock Exchange. Formed through the acquisition of UCB’s China neurology and allergy business, NeuroGen markets six products—including Keppra, Vimpat, Neupro, and Xyzal—and recently secured BLA approval for Ajovy. The company reported RMB 1.32 billion in revenue and RMB 153.7 million net profit for FY2025, with strong gross margins (47.9%) and a lean R&D model focused on licensing mid-to-late-stage assets. Backed equally by CBC Group and Mubadala Investment Company, NeuroGen operates one of China’s largest dedicated neurology sales teams and emphasizes outpatient channels to mitigate Volume-Based Procurement risks.

It is precisely due to the in-depth research into the neural mechanisms underlying addiction that Neurestora® multicenter clinical trial data demonstrate significantly superior outcomes compared to traditional drug detoxification regimens, with particularly prominent long-term efficacy advantages: the 6-month abstinence rate (non-relapse rate) reaches 80%, approximately 70% of patients achieve 10-year abstinence, and some patients can have the device removed after two years of treatment, allowing them to return to normal daily life.

Beijing Grit Biotherapeutics has received IND approval from China's NMPA for GT101, a tumor-infiltrating lymphocyte (TIL) therapy, for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. This marks China's first approved clinical trial for a TIL therapy in this indication. GT101 has previously demonstrated promising efficacy in cervical cancer, achieving a 45.5% objective response rate and complete remission in a patient, as presented at the ASCO annual meeting. Grit Biotherapeutics continues to expand its pipeline of innovative cellular therapies targeting solid tumors.

Jiangsu Hengrui Pharmaceuticals has secured NMPA approval for Airlui® (Adebrelimab Injection) in combination with platinum-based chemotherapy as neoadjuvant therapy, followed by Adebrelimab monotherapy as adjuvant treatment, for adult patients with resectable stage II, IIIA, and IIIB non-small cell lung cancer (NSCLC) without EGFR mutations or ALK rearrangements. This marks the first approval of a domestically developed PD-L1 inhibitor for perioperative NSCLC treatment in China and the drug's second lung cancer indication. The approval is based on the phase Ib/III SHR-1316-III-303 trial led by Professor Wu Yilong, which enrolled 501 patients and demonstrated a major pathological response (MPR) rate of 53.8% versus 18.4% with placebo (p<0.0001), a pathological complete response (pCR) rate of 31.1% versus 7.6%, and a two-year event-free survival (EFS) rate of 74.8% versus 55.5%, representing a 48% reduction in the risk of disease recurrence, progression, or death (HR=0.52). The surgery rate reached 88.8%, the highest reported in similar perioperative lung cancer trials, with a consistent safety profile and no new safety signals identified.

China's Center for Drug Evaluation (CDE) has accepted the clinical trial application for HS-20110, a novel antibody-drug conjugate (ADC) targeting CDH17 developed by Hansoh Pharmaceutical for gastrointestinal cancers. This regulatory milestone follows a major licensing agreement with Roche valued at over $1.5 billion, granting Roche exclusive global rights outside of Greater China. As Hansoh's third ADC licensed to a multinational partner, HS-20110 is advancing rapidly through clinical trials in both China and the U.S., underscoring its strong potential in treating highly prevalent and deadly solid tumors.

Shanghai Huaota Biopharmaceutical Co., Ltd., a subsidiary of Huahai Pharmaceutical, has announced that China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for HB0017, a Class 1 innovative anti-IL-17A monoclonal antibody injection for the treatment of moderate-to-severe plaque psoriasis, with application number CXSS2600100, as of June 24, 2026. This marks Huaota's first product to reach the regulatory milestone for commercial approval. The pivotal Phase III clinical trial, led by Professor Zhang Jianzhong and Professor Zhou Cheng at Peking University People's Hospital, enrolled 408 patients across more than 40 research centers in China. Top-line data revealed that after 12 weeks of treatment, 95.7% of patients in the HB0017 group achieved PASI 75, compared with only 7.4% in the placebo group. Additionally, 87.0% of patients achieved sPGA 0/1 (clear or almost clear skin) versus 1.9% for placebo, and 88.0% achieved PASI 90. A key differentiator of HB0017 is its maintenance-phase dosing advantage, with the dosing interval extendable to once every eight weeks while sustaining stable efficacy. At 52 weeks, 92.3% of patients in the every-four-weeks group maintained sPGA 0/1 response, and 79.1% maintained PASI 100 (complete clearance), while the every-eight-weeks group showed 85.9% sPGA 0/1 and 65.8% PASI 100 maintenance rates. The safety profile was consistent with expectations, with no new safety signals identified. Beyond psoriasis, Huaota is also advancing a Phase III trial of HB0017 for ankylosing spondylitis. With cumulative R&D investment of approximately RMB 372 million, HB0017 is well positioned to compete in the rapidly growing IL-17A monoclonal antibody market in China, alongside existing products from Novartis, Eli Lilly, Genoray Biopharma, and Hengrui Medicine.

China's NMPA Center for Drug Evaluation (CDE) has accepted a new drug application from Chia Tai Tianqing for TQB2922, a subcutaneous EGFR/c-Met bispecific antibody, under acceptance number CXSL2600667 on June 24, 2026. TQB2922 employs a dual mechanism—inhibiting EGFR and c-Met signaling pathways while recruiting natural killer cells and macrophages to target cancer cells—aimed at overcoming resistance to third-generation EGFR TKIs in non-small cell lung cancer (NSCLC). Phase I data presented at the 2026 ELCC demonstrated an objective response rate of 23.7% as monotherapy and 64.7% in combination with chemotherapy and bevacizumab, with a manageable safety profile. The company is also developing a proprietary subcutaneous formulation to improve patient convenience. As Johnson & Johnson's amivantamab remains the only approved product in this space, multiple Chinese biotech firms are intensifying competition in the high-stakes EGFR/c-Met bispecific antibody arena.